Trial Profile
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 13 Jun 2022 Status changed from recruiting to completed.
- 21 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Aug 2020.
- 17 May 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.